Adult onset Still's disease: a study of 14 cases.
We studied the clinical profile, laboratory parameters, disease course, and outcomes of patients with adult onset Still's disease (AOSD). A retrospective analysis of adult patients with Still's disease diagnosed from 2000 to 2004 was carried out. Their clinical features and laboratory findings at presentation, disease course, and outcomes were analyzed. Data of 14 patients with Still's disease were analyzed. The age at disease onset ranged from 16 to 59 years with a mean of 29.85, the male to female ratio being 9:5. The mean duration of illness from onset of symptoms to presentation was 14.5 months (range). The most common clinical manifestations were fever (n = 14), articular symptoms (n = 14), rash (n = 8), weight loss (n = 12), and sore throat (n = 5). Elevated ESR was present in all patients with a mean of 98.3 mm at 1 h. Hepatic enzymes were elevated in seven patients at disease onset. The mean duration of follow up was 19.14 months (range). Three patients progressed to chronic arthropathy. Cyclosporine led to dramatic recovery in five patients. Macrophage activation syndrome (MAS) was present in two patients, one after sulfasalazine therapy. One patient with MAS died. Still's disease, although uncommon, has characteristic constellation of clinical and laboratory features and should be considered in the differential diagnosis of fever of unknown origin. Nonsteroidal anti-inflammatory drugs, steroids, and methotrexate may not be always effective, and cyclosporine is an effective drug in resistant cases. Sulfasalazine should be avoided in cases of AOSD.
Singh
S
S
Department of Rheumatology, P.D. Hinduja National Hospital & Medical Research Center, V.S Marg, Mahim (w), Mumbai-16, India.
Samant
R
R
Joshi
V R
VR
D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000075202:Contraindications; D016572:Cyclosporine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005076:Exanthema / Q000209:etiology / Q000473:pathology; D005260:Female; D005334:Fever / Q000209:etiology / Q000473:pathology; D005335:Fever of Unknown Origin / Q000175:diagnosis; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007592:Joint Diseases / Q000209:etiology / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D016706:Still's Disease, Adult-Onset / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D012460:Sulfasalazine; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D012460:Sulfasalazine; D016572:Cyclosporine; D008727:Methotrexate
J Formos Med Assoc. 2004 Nov;103(11):844-52
15549152
Br J Rheumatol. 1991 Apr;30(2):158
2012954
South Med J. 1980 May;73(5):555-63
7375968
Arthritis Rheum. 1982 May;25(5):579-82
7082403
Curr Opin Rheumatol. 2002 Sep;14(5):548-52
12192253
Ann Rheum Dis. 2004 May;63(5):605
15082500
Br J Rheumatol. 1992 Jun;31(6):417-9
1596706
Lancet. 1987 Mar 7;1(8532):562-3
2881109
Clin Rheumatol. 2003 May;22(2):89-93
12740670
Presse Med. 2004 Sep 11;33(15):1019-26
15523252
J Rheumatol. 1997 Aug;24(8):1582-7
9263155
J Rheumatol. 1992 Mar;19(3):424-30
1578458
Clin Exp Rheumatol. 2000 Mar-Apr;18(2):245-8
10812499
Arthritis Rheum. 1976 Mar-Apr;19(2):232-42
1259802
Medicine (Baltimore). 1984 Mar;63(2):82-91
6700435
Ann Rheum Dis. 1992 Apr;51(4):529-32
1586255
Ann Rheum Dis. 1971 Mar;30(2):121-33
5315135
Ann Rheum Dis. 1992 Nov;51(11):1264-5
1361319